330 related articles for article (PubMed ID: 27635234)
1. Virotherapy: cancer gene therapy at last?
Bilsland AE; Spiliopoulou P; Evans TR
F1000Res; 2016; 5():. PubMed ID: 27635234
[TBL] [Abstract][Full Text] [Related]
2. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
3. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
[TBL] [Abstract][Full Text] [Related]
4. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
5. Talimogene laherparepvec: overview, combination therapy and current practices.
O'Donoghue C; Doepker MP; Zager JS
Melanoma Manag; 2016 Dec; 3(4):267-272. PubMed ID: 30190898
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Burke EE; Zager JS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
[TBL] [Abstract][Full Text] [Related]
8. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
9. Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer.
Coffin R
Immunotherapy; 2016 Feb; 8(2):103-6. PubMed ID: 26799112
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of talimogene laherparepvec for the treatment of melanoma.
Broman KK; Zager JS
Expert Opin Biol Ther; 2020 Jan; 20(1):9-14. PubMed ID: 31690129
[No Abstract] [Full Text] [Related]
11. Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes.
Orloff M
Oncolytic Virother; 2016; 5():91-98. PubMed ID: 27785448
[TBL] [Abstract][Full Text] [Related]
12. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Bommareddy PK; Patel A; Hossain S; Kaufman HL
Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
[TBL] [Abstract][Full Text] [Related]
13. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
14. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
15. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries.
van Akkooi ACJ; Haferkamp S; Papa S; Franke V; Pinter A; Weishaupt C; Huber MA; Loquai C; Richtig E; Gokani P; Öhrling K; Louie KS; Mohr P
Adv Ther; 2021 Feb; 38(2):1245-1262. PubMed ID: 33368016
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma.
Ahamadi M; Kast J; Chen PW; Huang X; Dutta S; Upreti VV
CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):250-260. PubMed ID: 36564918
[TBL] [Abstract][Full Text] [Related]
18. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
[TBL] [Abstract][Full Text] [Related]
19. Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.
Zhang T; Jou TH; Hsin J; Wang Z; Huang K; Ye J; Yin H; Xing Y
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769745
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Viruses for the Treatment of Metastatic Melanoma.
Trager MH; Geskin LJ; Saenger YM
Curr Treat Options Oncol; 2020 Mar; 21(4):26. PubMed ID: 32266483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
